Immunomedics of Morris Plains, NJ, hopes to develop a new class of cancer therapy products based on a genetically engineered protein, the company has announced.
Immunomedics executives are calling the new technology a bispecific antibody fusion protein. It could be used to develop a two-step drug delivery method for cancer therapy. The protein is manufactured by linking portions of the genes that encode two distinct antibodies, yielding a single protein molecule with two binding sites: one to the tumor and the other to a small molecule carrying a therapeutic agent.
In a recent presentation at the Antibody Engineering Conference in San Diego, researchers demonstrated the protein's ability to bind to human cancers grown in animals. The protein reportedly showed higher uptake in cancerous tissues than other, more conventional forms of antibody binding.
By AuntMinnie.com staff writers
December 29, 1999
Copyright © 1999 AuntMinnie.com
